Unique ID issued by UMIN | UMIN000028286 |
---|---|
Receipt number | R000032385 |
Scientific Title | The utility of the early intervention by the multi-disciplinary cooperation in the skin reaction due to EGFR inhibitor: Phase II study |
Date of disclosure of the study information | 2017/09/01 |
Last modified on | 2024/07/24 12:06:09 |
The utility of the early intervention by the multi-disciplinary cooperation in the skin reaction due to EGFR inhibitor: Phase II study
The utility of the early intervention by the multi-disciplinary cooperation in the skin reaction due to EGFR inhibitor: Phase II study
The utility of the early intervention by the multi-disciplinary cooperation in the skin reaction due to EGFR inhibitor: Phase II study
The utility of the early intervention by the multi-disciplinary cooperation in the skin reaction due to EGFR inhibitor: Phase II study
Japan |
colorectal cancer, head and neck cancer
Hepato-biliary-pancreatic medicine | Gastrointestinal surgery | Oto-rhino-laryngology |
Oral surgery |
Malignancy
NO
We appear at high frequency in order of rash, dry skin, perionychia, and the skin reaction with the EGFR (epidermal growth factor receptor) inhibitor often causes the treatment cancellation. Therefore skin reaction measures with the supportive care become important. In the current study, we examine a utility of the early intervention by the multi-disciplinary (dermatologist, medical oncologist, head and neck surgeon, digestive organ surgeon, pharmacist, nurse) cooperation in the skin reaction due to EGFR inhibitor.
Efficacy
Pragmatic
Phase II
Severe skin reaction incidence
utility of the episode of care sheet
TTF
Chemotherapy cancellation ratio due to the skin reaction
Interventional
Single arm
Non-randomized
Open -no one is blinded
Uncontrolled
No need to know
1
Treatment
Medicine |
We conduct an introduction to the chemotherapy center from diagnosis and treatment department, and, in chemotherapy center, a medical oncologist, a pharmacist or a nurse conducts side effect monitoring using an episode of care sheet (the skin reaction monitoring sheet that we made for the purpose of doing multi-disciplinary cooperation smoothly) at chemotherapy enforcement. By severity of the skin reaction, a tumor physician refers you to a dermatologist, and side effect monitoring, a dermatologist intervene after the next treatment.
Not applicable |
Not applicable |
Male and Female
The patients who are given EGFR inhibitor with a newcomer
The patients who have experience using EGFR inhibitors, but do not have skin symptoms at the time of re-administration
The patients that an agreement was not obtained
The patients who have difficulty in side effect monitoring
55
1st name | |
Middle name | |
Last name | Shohei Sano |
Wakayama Medical University hospital
Pharmacy
811-1, Kimiidera, Wakayama-shi
073-447-2300
s-sano@wakayama-med.ac.jp
1st name | |
Middle name | |
Last name | Shohei Sano |
Wakayama Medical University hospital
Pharmacy
811-1, Kimiidera, Wakayama-shi
073-447-2300
s-sano@wakayama-med.ac.jp
Wakayama Medical University hospital
Self-funding
Self funding
NO
和歌山県立医科大学附属病院(和歌山)Wakayama Medical University hospital
2017 | Year | 09 | Month | 01 | Day |
Unpublished
Completed
2017 | Year | 07 | Month | 21 | Day |
2017 | Year | 09 | Month | 05 | Day |
2017 | Year | 09 | Month | 07 | Day |
2022 | Year | 09 | Month | 05 | Day |
2022 | Year | 09 | Month | 05 | Day |
2022 | Year | 09 | Month | 05 | Day |
2023 | Year | 09 | Month | 05 | Day |
2017 | Year | 07 | Month | 19 | Day |
2024 | Year | 07 | Month | 24 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000032385